{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:30:04Z","timestamp":1794047404892,"version":"4.8.0"},"reference-count":42,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"10","license":[{"start":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T00:00:00Z","timestamp":1648684800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>Chimeric antigen receptor (CAR) T-cell based immunotherapy has become a promising treatment mainly for hematological malignancies. Following the major success of CD19-targeted CAR, new potential targets for other malignancies are required. As such, B-cell maturation antigen (BCMA) is an attractive tumor-associated antigen to be targeted in multiple myeloma (MM). Herein, we aimed at assessing the function and optimal configuration of different BCMA-specific CAR, based on the same targeting moiety but with a different hinge and co-stimulatory domain. We compared their function to that of a previously characterized BCMA-CAR used in clinical trials. All constructs were expressed at high levels by primary human T cells and could trigger cytokine production and cytotoxicity upon co-culture with multiple myeloma targets. Nonetheless, critical differences were observed in off-target activation, exhaustion, and activation marker expression and in vivo antitumoral activity mediated by these different constructs. Interestingly, we noted that CD8-based hinge, combined with a 4-1BB intracellular domain, proved superior compared to IgG4-connecting regions, and\/or a CD28-signaling moiety respectively. Overall, this study emphasizes the influence of CAR primary structure on its function and led to the identification of a highly efficient BCMA-specific CAR, namely H8BB, which displayed superior anti-tumoral activity both in vitro and long-term in vivo efficacy.<\/jats:p>","DOI":"10.3324\/haematol.2021.280169","type":"journal-article","created":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T03:15:07Z","timestamp":1648696507000},"page":"2395-2407","source":"Crossref","is-referenced-by-count":19,"title":["Preclinical evaluation and structural optimization of anti-BCMA CAR to target multiple myeloma"],"prefix":"10.3324","volume":"107","author":[{"given":"Ortal","family":"Harush","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Asherie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shlomit","family":"Kfir-Erenfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Galit","family":"Adler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tilda","family":"Barliya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miri","family":"Assayag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moshe E.","family":"Gatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Polina","family":"Stepensky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cyrille J.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2022,3,31]]},"reference":[{"key":"40335","doi-asserted-by":"crossref","unstructured":"Bu DX, Singh R, Choi EE. Pre-clinical validation of B cell maturation antigen (BCMA) as a target for T cell immunotherapy of multiple myeloma. Oncotarget. 2018; 9(40):25764-25780.","DOI":"10.18632\/oncotarget.25359"},{"key":"40336","doi-asserted-by":"crossref","unstructured":"Palumbo A, Anderson K. Multiple myeloma. N Engl J Med. 2011; 364(119):1046-1060.","DOI":"10.1056\/NEJMra1011442"},{"key":"40337","doi-asserted-by":"crossref","unstructured":"Cho SF, Anderson KC, Tai YT. Targeting B cell maturation antigen (BCMA) in multiple myeloma: potential uses of BCMA-based immunotherapy. Front Immunol. 2018; 9:1821.","DOI":"10.3389\/fimmu.2018.01821"},{"key":"40338","doi-asserted-by":"crossref","unstructured":"Meinl E, Thaler FS, Lichtenthaler SF. Shedding of BAFF\/APRIL receptors controls B cells. Trends Immunol. 2018; 39(9):673-676.","DOI":"10.1016\/j.it.2018.07.002"},{"key":"40339","doi-asserted-by":"crossref","unstructured":"Friedman KM, Garrett TE, Evans JW. Effective targeting of multiple B-cell maturation antigen-expressing hematological malignances by anti-B-cell maturation antigen chimeric antigen receptor T cells. Hum Gene Ther. 2018; 29(5):585-601.","DOI":"10.1089\/hum.2018.001"},{"key":"40340","doi-asserted-by":"crossref","unstructured":"Ghosh A, Mailankody S, Giralt SA. CAR T cell therapy for multiple myeloma: where are we now and where are we headed?. Leuk Lymphoma. 2018; 59(9):2056-2067.","DOI":"10.1080\/10428194.2017.1393668"},{"key":"40341","doi-asserted-by":"crossref","unstructured":"Carpenter RO, Evbuomwan MO, Pittaluga S. B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma. Clin.Cancer Res. 2013; 19(8):2048-2060.","DOI":"10.1158\/1078-0432.CCR-12-2422"},{"key":"40342","doi-asserted-by":"crossref","unstructured":"Ali SA, Shi V, Maric I. T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma. Blood. 2016; 128(13):1688-1700.","DOI":"10.1182\/blood-2016-04-711903"},{"key":"40343","doi-asserted-by":"crossref","unstructured":"Brudno JN, Maric I, Hartman SD. T cells genetically modified to express an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of poor-prognosis relapsed multiple myeloma. J Clin Oncol. 2018; 36(22):2267-2280.","DOI":"10.1200\/JCO.2018.77.8084"},{"key":"40344","doi-asserted-by":"crossref","unstructured":"Raje N, Berdeja J, Lin Y. Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma. N Engl J Med. 2019; 380(18):1726-1737.","DOI":"10.1056\/NEJMoa1817226"},{"key":"40345","doi-asserted-by":"crossref","unstructured":"Cohen AD, Garfall AL, Stadtmauer EA. B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma. J Clin Invest. 2019; 129(6):2210-2221.","DOI":"10.1172\/JCI126397"},{"key":"40346","doi-asserted-by":"crossref","unstructured":"Jiang S, Jin J, Hao S. Low dose of human scFv-derived BCMA-targeted CAR-T cells achieved fast response and high complete remission in patients with relapsed\/refractory multiple myeloma. Blood. 2018; 132(Suppl 1):S960.","DOI":"10.1182\/blood-2018-99-113220"},{"key":"40347","doi-asserted-by":"crossref","unstructured":"Liu Y, Chen Z, Fang H. Durable remission achieved from Bcma-directed CAR-T therapy against relapsed or refractory multiple myeloma. Blood. 2018; 132(Suppl 1):S956.","DOI":"10.1182\/blood-2018-99-112786"},{"key":"40348","doi-asserted-by":"crossref","unstructured":"Mailankody S, Ghosh A, Staehr M. Clinical responses and pharmacokinetics of MCARH171, a human-derived Bcma targeted CAR T cell therapy in relapsed\/refractory multiple myeloma: final results of a phase I clinical trial. Blood. 2018; 132(Suppl 1):S959.","DOI":"10.1182\/blood-2018-99-119717"},{"key":"40349","doi-asserted-by":"crossref","unstructured":"Munshi NC, Anderson LD, Shah N. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med. 2021; 384(8):705-716.","DOI":"10.1056\/NEJMoa2024850"},{"key":"40350","doi-asserted-by":"crossref","unstructured":"Berdeja JG, Madduri D, Usmani SZ. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study. Lancet. 2021; 398(10297):314-324.","DOI":"10.1016\/S0140-6736(21)00933-8"},{"key":"40351","doi-asserted-by":"crossref","unstructured":"Kawalekar OU, O'Connor RS, Fraietta JA. Distinct signaling of coreceptors regulates specific metabolism pathways and impacts memory development in CAR T cells. Immunity. 2016; 44(2):380-390.","DOI":"10.1016\/j.immuni.2016.01.021"},{"key":"40352","doi-asserted-by":"crossref","unstructured":"Fujiwara K, Tsunei A, Kusabuka H. Hinge and transmembrane domains of chimeric antigen receptor regulate receptor expression and signaling threshold. Cells. 2020; 9(5):1182.","DOI":"10.3390\/cells9051182"},{"key":"40353","doi-asserted-by":"crossref","unstructured":"Alabanza L, Pegues M, Geldres C. Function of novel anti-CD19 chimeric antigen receptors with human variable regions is affected by hinge and transmembrane domains. Mol Ther. 2017; 25(11):2452-2465.","DOI":"10.1016\/j.ymthe.2017.07.013"},{"key":"40354","doi-asserted-by":"crossref","unstructured":"Hudecek M, Sommermeyer D, Kosasih PL. The nonsignaling extracellular spacer domain of chimeric antigen receptors is decisive for in vivo antitumor activity. Cancer Immunol Res. 2015; 3(2):125-135.","DOI":"10.1158\/2326-6066.CIR-14-0127"},{"key":"40355","doi-asserted-by":"crossref","unstructured":"Hudecek M, Lupo-Stanghellini MT, Kosasih PL. Receptor affinity and extracellular domain modifications affect tumor recognition by ROR1-specific chimeric antigen receptor T cells. Clin Cancer Res. 2013; 19(12):3153-3164.","DOI":"10.1158\/1078-0432.CCR-13-0330"},{"key":"40356","doi-asserted-by":"crossref","unstructured":"James SE, Greenberg PD, Jensen MC. Antigen sensitivity of CD22-specific chimeric TCR is modulated by target epitope distance from the cell membrane. J Immunol. 2008; 180(10):7028-7038.","DOI":"10.4049\/jimmunol.180.10.7028"},{"key":"40357","doi-asserted-by":"crossref","unstructured":"Davey AS, Call ME, Call MJ. The influence of chimeric antigen receptor structural domains on clinical outcomes and associated toxicities. Cancers (Basel). 2020; 13(1):38.","DOI":"10.3390\/cancers13010038"},{"key":"40358","doi-asserted-by":"crossref","unstructured":"Daniel-Meshulam I, Horovitz-Fried M, Cohen CJ. Enhanced antitumor activity mediated by human 4-1BB-engineered T cells. Int J Cancer. 2013; 13(12):2903-2913.","DOI":"10.1002\/ijc.28320"},{"key":"40359","doi-asserted-by":"crossref","unstructured":"Eisenberg V, Shamalov K, Meir S. Targeting multiple tumors using T-cells engineered to express a natural cytotoxicity receptor 2-based chimeric receptor. Front Immunol. 2017; 8:1212.","DOI":"10.3389\/fimmu.2017.01212"},{"key":"40360","doi-asserted-by":"crossref","unstructured":"Meril S, Harush O, Reboh Y. Targeting glycosylated antigens on cancer cells using siglec-7\/9-based CAR T-cells. Mol Carcinog. 2020; 59(7):713-723.","DOI":"10.1002\/mc.23213"},{"key":"40361","doi-asserted-by":"crossref","unstructured":"Liu L, Sommermeyer D, Cabanov A. Inclusion of Strep-tag II in design of antigen receptors for T-cell immunotherapy. Nat Biotechnol. 2016; 34(4):430-434.","DOI":"10.1038\/nbt.3461"},{"key":"40362","doi-asserted-by":"crossref","unstructured":"Hoogi S, Eisenberg V, Mayer S. A TIGIT-based chimeric co-stimulatory switch receptor improves T-cell anti-tumor function. J Immunother Cancer. 2019; 7(1):243.","DOI":"10.1186\/s40425-019-0721-y"},{"key":"40363","doi-asserted-by":"crossref","unstructured":"Shamalov K, Levy SN, Horovitz-Fried M, Cohen CJ. The mutational status of p53 can influence its recognition by human T-cells. Oncoimmunology. 2017; 6(4):e1285990.","DOI":"10.1080\/2162402X.2017.1285990"},{"key":"40364","doi-asserted-by":"crossref","unstructured":"Tal Y, Yaakobi S, Horovitz-Fried M. An NCR1-based chimeric receptor endows T-cells with multiple anti-tumor specificities. Oncotarget. 2014; 5(21):10949-10958.","DOI":"10.18632\/oncotarget.1919"},{"key":"40365","doi-asserted-by":"crossref","unstructured":"Eisenberg V, Hoogi S, Shamul A, Barliya T, Cohen CJ. T-cells &quot;a la CAR-T(e)&quot; - genetically engineering T-cell response against cancer. Adv Drug Deliv Rev. 2019; 141:23-40.","DOI":"10.1016\/j.addr.2019.01.007"},{"key":"40366","doi-asserted-by":"crossref","unstructured":"Wilde S, Sommermeyer D, Leisegang M. Human antitumor CD8+ T cells producing Th1 polycytokines show superior antigen sensitivity and tumor recognition. J Immunol. 2012; 189(2):598-605.","DOI":"10.4049\/jimmunol.1102165"},{"key":"40367","doi-asserted-by":"crossref","unstructured":"Ren H, Cao K, Wang M. A correlation between differentiation phenotypes of infused T cells and anti-cancer immunotherapy. Front Immunol. 2021; 12:745109.","DOI":"10.3389\/fimmu.2021.745109"},{"key":"40368","doi-asserted-by":"crossref","unstructured":"Anderson AC, Joller N, Kuchroo VK. Lag-3, Tim-3, and TIGIT: co-inhibitory receptors with specialized functions in immune regulation. Immunity. 2016; 44(5):989-1004.","DOI":"10.1016\/j.immuni.2016.05.001"},{"key":"40369","doi-asserted-by":"crossref","unstructured":"Long AH, Haso WM, Shern JF. 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors. Nat Med. 2015; 21(6):581-590.","DOI":"10.1038\/nm.3838"},{"key":"40370","doi-asserted-by":"crossref","unstructured":"Han G, Chen G, Shen B, Li Y. Tim-3: an activation marker and activation limiter of innate immune cells. Front Immunol. 2013; 4:449.","DOI":"10.3389\/fimmu.2013.00449"},{"key":"40371","doi-asserted-by":"crossref","unstructured":"Ghermezi M, Li M, Vardanyan S. Serum B-cell maturation antigen: a novel biomarker to predict outcomes for multiple myeloma patients. Haematologica. 2017; 102(4):785-795.","DOI":"10.3324\/haematol.2016.150896"},{"key":"40372","doi-asserted-by":"crossref","unstructured":"Bal S, Sigler A, Chan A. First Description of B cell maturation antigen expression in light chain amyloidosis. Blood. 2019; 134(Suppl 1):S5452.","DOI":"10.1182\/blood-2019-127332"},{"key":"40373","doi-asserted-by":"crossref","unstructured":"Guedan S, Calderon H, Posey AD, Maus MV. Engineering and design of chimeric antigen receptors. Mol Ther Methods Clin Dev. 2018; 12:145-156.","DOI":"10.1016\/j.omtm.2018.12.009"},{"key":"40374","doi-asserted-by":"crossref","unstructured":"Lindner SE, Johnson SM, Brown CE, Wang LD. Chimeric antigen receptor signaling: functional consequences and design implications. Sci Adv. 2020; 6(21):eaaz3223.","DOI":"10.1126\/sciadv.aaz3223"},{"key":"40375","doi-asserted-by":"crossref","unstructured":"Smith EL, Harrington K, Staehr M. GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells. Sci Transl Med. 2019; 11(485):eaau7746.","DOI":"10.1126\/scitranslmed.aau7746"},{"key":"40376","doi-asserted-by":"crossref","unstructured":"Ying Z, Huang XF, Xiang X. A safe and potent anti-CD19 CAR T cell therapy. Nat Med. 2019; 25(6):947-953.","DOI":"10.1038\/s41591-019-0421-7"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2021.280169\/74320","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2021.280169\/74882","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/10592\/74320","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:01:24Z","timestamp":1794045684000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/haematol.2021.280169"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,31]]},"references-count":42,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2022,10,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2021.280169","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3,31]]}}}